Shares of OBI Pharma Inc (台灣浩鼎) yesterday fell by the maximum daily limit of 10 percent to close at NT$613, after the company on Sunday released discouraging results on the second and third-phase clinical trials of a new breast cancer drug, OBI-822.
OBI-822 remains an effective treatment option and the trial’s less promising than expected outcome stemmed from a number of factors, OBI Pharma chairman Michael Chang (張念慈) told an investors’ conference yesterday.
The drug is designed to target Globo H, an oligosaccharide tumor antigen, by triggering the human body’s immune system to generate antibodies that activate cytotoxic T cells to destroy cancer cells, and more than 80 percent of the participants in the trials had generated immune system responses, he said.
Among the participants who showed immune responses, most had made good progress in recovery, while maintaining a safe level of toxicity of the drug.
“About 20 percent of participants did not generate immune responses, and their results should not have been included in the study,” Chang said.
The parameters of the study were set in 2009, and the company elected to go ahead with the trials even though it had discovered flaws in the methodology, he said.
In addition, the study had neglected to select participants based on whether they showed an ample presence of Globo H, Chang said.
Immune responses are not statistically significant without the oligosaccharide, he said.
The flawed design of the study prematurely ruled out many potential participants before they had time to go through the eight-to-nine-week dormant period it is believed to take for the immune responses to develop, he said.
Chang said that he and the company’s other major stakeholders are planning to initiate a share buyback program.
Academia Sinica President Wong Chi-huey (翁啟惠), a close collaborator with the company, said he considers an 80 percent immune response as a statistically successful outcome, in particular among people in the more terminal stages of their diseases, who have diminished immune systems.
The objective of clinical trials is to determine which drugs prove to be effective and the focus should be placed on the outcome of participants who have developed an immune response, Wong said.
Excluding those without an immune response would present a more statistically significant outcome, Wong said, and he urged health authorities to devise new criteria for different treatments.
Yesterday’s plunge in OBI Pharma shares dragged down the biotechnology and medical care sub-index on the Taipei Exchange, which fell 5.17 percent to 178.9 points, the lowest since November last year, with many other high-priced sector leaders also seeing steep declines, TPEX data showed.
Analysts said that they do not expect a catastrophic crash in OBI Pharma share prices, as the company’s backers include the deep-pocketed Runtex Group (潤泰集團).
ENERGY ISSUES: The TSIA urged the government to increase natural gas and helium reserves to reduce the impact of the Middle East war on semiconductor supply stability Chip testing and packaging service provider ASE Technology Holding Co (日月光投控) yesterday said it planned to invest more than NT$100 billion (US$3.15 billion) in building a new advanced chip testing facility in Kaohsiung to keep up with customer demand driven by the artificial intelligence (AI) boom. That would be included in the company’s capital expenditure budget next year, ASE said. There is also room to raise this year’s capital spending budget from a record-high US$7 billion estimated three months ago, it added. ASE would have six factories under construction this year, another record-breaking number, ASE chief operating officer Tien Wu
The EU and US are nearing an agreement to coordinate on producing and securing critical minerals, part of a push to break reliance on Chinese supplies. The potential deal would create incentives, such as minimum prices, that could advantage non-Chinese suppliers, according to a draft of an “action plan” seen by Bloomberg. The EU and US would also cooperate on standards, investments and joint projects, as well as coordinate on any supply disruptions by countries like China. The two sides are additionally seeking other “like-minded partners” to join a multicountry accord to help create these new critical mineral supply chains, which feed into
For weeks now, the global tech industry has been waiting for a major artificial intelligence (AI) launch from DeepSeek (深度求索), seen as a benchmark for China’s progress in the fast-moving field. More than a year has passed since the start-up put Chinese AI on the map in early last year with a low-cost chatbot that performed at a similar level to US rivals. However, despite reports and rumors about its imminent release, DeepSeek’s next-generation “V4” model is nowhere in sight. Speculation is also swirling over the geopolitical implications of which computer chips were chosen to train and power the new
Intel Corp is joining Elon Musk’s long-shot effort to develop semiconductors for Tesla Inc, Space Exploration Technologies Corp and xAI, marking a surprising twist in the chipmaker’s comeback bid. Intel would help the Terafab project “refactor” the technology in a chip factory, the company said on Tuesday in a post on X, Musk’s social media platform. That is a stage in the development process that typically helps make chips more powerful or reliable. The chipmaker’s shares jumped 4.2 percent to US$52.91 in New York trading on Tuesday. The Terafab project is a grand plan by Musk to eventually manufacture his own chips for
RSS